Chris Moertel

Chris Moertel currently serves as the Chief Medical Officer at OX2 Therapeutics, Inc., a position held since January 2017. In addition, Chris Moertel has been a Clinical Director of Neuro-oncology and a Professor of Medicine at the University of Minnesota since September 2007. Educationally, Chris Moertel obtained a BA in Biology from St. Olaf College between 1972 and 1976 and is pursuing a Doctor of Medicine degree at the University of Minnesota School of Medicine since July 1980.